196 related articles for article (PubMed ID: 17521951)
1. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver.
Liao YC; Lo SH
Int J Biochem Cell Biol; 2008; 40(5):843-7. PubMed ID: 17521951
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function.
Liao YC; Shih YP; Lo SH
Cancer Res; 2008 Oct; 68(19):7718-22. PubMed ID: 18829524
[TBL] [Abstract][Full Text] [Related]
3. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1.
Liao YC; Si L; deVere White RW; Lo SH
J Cell Biol; 2007 Jan; 176(1):43-9. PubMed ID: 17190795
[TBL] [Abstract][Full Text] [Related]
4. The Role of Tumor Suppressor DLC-1: Far From Clear.
Liu X; Pan YJ; Zheng JN; Pei DS
Anticancer Agents Med Chem; 2017; 17(7):896-901. PubMed ID: 27604574
[TBL] [Abstract][Full Text] [Related]
5. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP.
Yuan BZ; Miller MJ; Keck CL; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 1998 May; 58(10):2196-9. PubMed ID: 9605766
[TBL] [Abstract][Full Text] [Related]
6. DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma.
Park SW; Durkin ME; Thorgeirsson SS; Popescu NC
Int J Oncol; 2003 Jul; 23(1):133-7. PubMed ID: 12792785
[TBL] [Abstract][Full Text] [Related]
7. Identifying Cancer-Relevant Mutations in the DLC START Domain Using Evolutionary and Structure-Function Analyses.
Holub AS; Bouley RA; Petreaca RC; Husbands AY
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142932
[TBL] [Abstract][Full Text] [Related]
8. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells.
Zhou X; Thorgeirsson SS; Popescu NC
Oncogene; 2004 Feb; 23(6):1308-13. PubMed ID: 14647417
[TBL] [Abstract][Full Text] [Related]
9. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
10. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.
Ching YP; Wong CM; Chan SF; Leung TH; Ng DC; Jin DY; Ng IO
J Biol Chem; 2003 Mar; 278(12):10824-30. PubMed ID: 12531887
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors.
Ullmannova V; Popescu NC
Int J Oncol; 2006 Nov; 29(5):1127-32. PubMed ID: 17016643
[TBL] [Abstract][Full Text] [Related]
12. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth.
Durkin ME; Ullmannova V; Guan M; Popescu NC
Oncogene; 2007 Jul; 26(31):4580-9. PubMed ID: 17297465
[TBL] [Abstract][Full Text] [Related]
13. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.
Ng IO; Liang ZD; Cao L; Lee TK
Cancer Res; 2000 Dec; 60(23):6581-4. PubMed ID: 11118037
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.
Wong CM; Lee JM; Ching YP; Jin DY; Ng IO
Cancer Res; 2003 Nov; 63(22):7646-51. PubMed ID: 14633684
[TBL] [Abstract][Full Text] [Related]
15. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity.
Yuan BZ; Zhou X; Durkin ME; Zimonjic DB; Gumundsdottir K; Eyfjord JE; Thorgeirsson SS; Popescu NC
Oncogene; 2003 Jan; 22(3):445-50. PubMed ID: 12545165
[TBL] [Abstract][Full Text] [Related]
16. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
18. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas.
Yuan BZ; Jefferson AM; Baldwin KT; Thorgeirsson SS; Popescu NC; Reynolds SH
Oncogene; 2004 Feb; 23(7):1405-11. PubMed ID: 14661059
[TBL] [Abstract][Full Text] [Related]
19. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.
Kim TY; Lee JW; Kim HP; Jong HS; Kim TY; Jung M; Bang YJ
Biochem Biophys Res Commun; 2007 Mar; 355(1):72-7. PubMed ID: 17292327
[TBL] [Abstract][Full Text] [Related]
20. Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.
Jaiswal M; Dvorsky R; Amin E; Risse SL; Fansa EK; Zhang SC; Taha MS; Gauhar AR; Nakhaei-Rad S; Kordes C; Koessmeier KT; Cirstea IC; Olayioye MA; Häussinger D; Ahmadian MR
J Biol Chem; 2014 Mar; 289(10):6839-6849. PubMed ID: 24443565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
